FDA approves new pediatric asthma drug
FDA approves new pediatric asthma drug
The Food and Drug Administration recently approved a new pediatric formulation of the asthma medication ACCOLATE, zafirlukast, manufactured by AstraZeneca Phar maceuticals in Wil mington, DE. Zafirlukast has been available for treatment of asthma sufferers over age 12 since 1996. The drug has been prescribed more than 5 million times for the preventative and chronic treatment of asthma. The new pediatric dose is approved for use in patients as young as 7. It is available in a 10 mg nonflavored, mini-tablet. Recommended dosage is one 10 mg mini tablet twice daily, even during symptom free periods.
Subscribe Now for Access
You have reached your article limit for the month. We hope you found our articles both enjoyable and insightful. For information on new subscriptions, product trials, alternative billing arrangements or group and site discounts please call 800-688-2421. We look forward to having you as a long-term member of the Relias Media community.